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ABSTRACT
Coregulators cooperate with nuclear receptors, such as the glucocorticoid 
receptor (GR), to enhance or repress transcription. These regulatory proteins are 
implicated in cancer, yet, their role in lymphoid malignancies, including multiple 
myeloma (MM) and acute lymphoblastic leukemia (ALL), is largely unknown. Here, 
we report the use and extension of the microarray assay for real-time nuclear receptor 
coregulator interactions (MARCoNI) technology to detect coregulator associations 
with endogenous GR in cell lysates. We use MARCoNI to determine the GR coregulator 
profile of glucocorticoid-sensitive (MM and ALL) and glucocorticoid-resistant (ALL) 
cells, and identify common and unique coregulators for different cell line comparisons. 
Overall, we identify SRC-1/2/3, PGC-1α, RIP140 and DAX-1 as the strongest 
interacting coregulators of GR in MM and ALL cells and show that the interaction 
strength does not correlate with GR protein levels. Lastly, as a step towards patient 
samples, we determine the GR coregulator profile of peripheral blood mononuclear 
cells. We profile the interactions between GR and coregulators in MM and ALL cells 
and suggest to further explore the GR coregulator profile in hematological patient 
samples.
INTRODUCTION
Coregulators are proteins that interact with nuclear 
receptors (NRs) and other transcription factors (TFs) 
to modulate gene transcription [1]. They are generally 
divided into two groups: coactivators, that interact 
(mostly) with agonist-bound NRs to promote gene 
transcription, and corepressors, that bind unliganded or 
antagonist-bound NRs to inhibit gene transcription [2, 
3]. However, this strict separation needs to be nuanced, 
since coactivators can act as corepressors and vice versa 
depending on the post-translational modification (PTM) 
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status of the coregulator, the NR and the promoter 
context [4, 5]. Coregulators are intricately involved in 
different physiological processes such as growth and 
development, reproduction and energy homeostasis, but 
also in pathological processes, including metabolic and 
reproductive diseases and cancers [4, 6].
Since transcription initiation is an ordered and 
dynamic process, coregulators with different structure 
and functions are essential [2] and so far, more than 
400 coregulators have been identified [7]. The first 
discovered NR coactivators were the steroid receptor 
coactivator (SRC) family, consisting of three members: 
SRC-1 (NCOA1), SRC-2 (NCOA2/GRIP1/TIF2) and 
SRC-3 (NCOA3/AIB1) [8]. Upon NR activation, SRCs 
are recruited to target gene promoters and act as adaptors, 
resulting in the formation of coactivator-dependent 
multiprotein complexes [2, 3]. To this end, SRCs, 
harboring weak intrinsic histone acetyltransferase activity, 
interact with other histone tail modifying coactivators 
such as histone acetyltransferases (HAT), e.g. cyclic 
AMP response-element binding protein (CREB)-binding 
protein (CBP) and p300 (a 300-kD homologue to CBP), 
and histone methyltransferases (HMT), e.g. co-activator 
associated methyltransferase 1 (CARM1) [9]. SRCs also 
engage the transcriptional mediator complex MED1 and 
recruit co-coactivators such as chromatin remodelers. 
In addition, SRC PTMs, including phosphorylation, 
acetylation and methylation, contribute to the association 
of the coactivator complex and affect the recruitment of 
the general TFs and RNA polymerase II [4, 9, 10].
Coactivators can also act as signal integrators [1]. 
In response to extracellular signals such as growth factors 
(e.g. epidermal growth factor (EGF)), cytokines (e.g. IL-
6) and steroid hormones, downstream signaling pathways 
are activated that utilize kinase cascades to phosphorylate 
coactivators such as SRCs. Depending on the SRC 
phosphorylation pattern, specific NRs or TFs and other 
coregulators are attracted to stimulate gene expression [9].
The glucocorticoid receptor (GR) is part of the NR 
superfamily and is stimulated by glucocorticoids (GCs). 
Upon activation, GR translocates to the nucleus where it 
recruits coregulators [11]. The mechanism by which GR 
modulates gene expression remains a heavily debated 
and controversial theme [12, 13]. As two extremes of 
many different mechanisms, activated GR can enhance 
the transcription of target genes (transactivation), or 
repress TF-driven (NF-κB, AP-1) gene expression 
(transrepression) [14, 15] at specific gene promoters. 
However, also non-genomic mechanisms are described, 
including the modulation of signaling pathways, e.g. 
MAPK by membrane-bound GR [16, 17].
GCs play a role in inflammation, immunity, 
metabolism, development, reproduction and cognition 
[18]. Therapeutically they are used in inflammatory 
and auto-immune disorders, but also in cancer [18]. In 
lymphoid malignancies such as multiple myeloma (MM) 
and acute lymphoblastic leukemia (ALL), GCs are an 
integral part of the treatment strategy [19]. In contrast 
to MM, which is a hematological disorder of terminally 
differentiated plasma cells and is localized in the bone 
marrow, ALL resides in the blood and is characterized by 
an uncontrolled proliferation of immature lymphocytes 
[20, 21]. Although GCs efficiently induce apoptosis 
of these malignant MM and ALL cells, prolonged 
administration of GCs entails two major limitations. 
First, there are the side-effects including e.g. diabetes, 
osteoporosis and edema [22], and second there is the 
emergence of GC resistance, of which the underlying 
mechanisms are manifold and often cell-type specific 
[19, 23, 24]. For instance, GR levels are important 
determinants of GC sensitivity and resistance and nuclear 
receptor corepressor 1 (NCOR1) was shown to contribute 
to the GC-induced GR gene repression mechanism and by 
extension to GC resistance [25].
In this study, we extended and used the microarray 
assay for real-time coregulator nuclear receptor 
interactions (MARCoNI) technology to monitor 
coregulator associations with endogenous GR of GC-
sensitive MM and ALL cells, GC-resistant ALL cells and 
lung carcinoma cells. MARCoNI uses PamChip arrays 
onto which 154 coregulator-derived peptides were spotted, 
each containing an NR-binding motif, including LXXLL 
for coactivators or LXXXIXXXL for corepressors, 
allowing the simultaneous detection of 67 coregulator 
interactions [26]. This technology was originally 
developed for recombinant or overexpressed NRs, but 
we extended its use to identify the coregulator profile of 
endogenous GR from a cellular context, which was, up till 
now, only reported for estrogen receptor ɑ (ERɑ) [27]. We 
identified common and unique coregulators in different 
cell line comparisons using MARCoNI and validated the 
results using co-immunoprecipitation. Signal intensities, 
quantifying the interaction between GR and a certain 
coregulator, were linked back to GR protein levels. As a 
step towards patient samples, we also determined the GR 
coregulator profile of peripheral blood mononuclear cells 
(PBMCs).
RESULTS
Coregulator profiling of MM and ALL cell lines 
using MARCoNI
We applied the MARCoNI technology to determine 
endogenous GR-coregulator interactions in cell lysates. In 
short, cell lysate containing endogenous GR is added on 
the PamChip together with a primary GR and a secondary 
detection antibody (Figure 1A). If an interaction between, 
in this case, a coactivator binding motif and GR takes 
place, a bright spot is observed in the readout. Therefore, it 
is the combined presence versus absence and the intensity 
of the spots that will determine the NR coregulator profile.
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We determined the endogenous GR coregulator 
profile of GC-sensitive MM and ALL cell lines, i.e. 
MM1.S and CEM-C7-14 (in short C7-14), respectively, 
and of a GC-resistant, yet GR-containing, ALL cell line, 
i.e. CEM-C1-15 (in short C1-15) [28, 29]. To this end, 
MM1.S, C7-14 and C1-15 cells were treated for 2h with 
solvent (EtOH) or Dex and subjected to MARCoNI 
analysis. Supplementary Figure 1 shows the coregulator 
peptides that interacted with endogenous GR in these cell 
lines with a mean signal intensity of more than 10 (cutoff) 
and ranked according to the Dex response. We further 
identified those coregulators that responded significantly 
to Dex treatment (Figure 1A-1C) and for which the 
corresponding p-values are listed in Table 1.
MM1.S cells showed the largest number (55) 
differentially responding coregulators and the highest 
signal intensity, i.e. strongest GR-coregulator interactions, 
when compared to C7-14 or C1-15 (resp. 18 and 11 
coregulators peptides) (Figure 1A-1C). Also, in MM1.S 
cells most coregulator peptides (52/55) showed increased 
signal intensity following Dex treatment, with PGC-1ɑ 
(PRGC1), SRC-1 (NCOA1), SRC-3 (NCOA3), SHP 
Figure 1: Coregulator profiling of endogenous GR in MM and ALL cells using MARCoNI. (A) MARCoNI principle. 
Cell lysates containing endogenous GR and the appropriate primary (anti-GR) and secondary (anti-Alexa 488) antibodies are added onto 
PamChip arrays, containing spotted coregulator peptides. Interactions between a coregulator peptide and GR result in a bright spot in the 
readout and are quantified. (B) MM1.S, (C) C7-14 or (D) C1-15 cells were treated for 2h with solvent or Dex (1μM). Protein lysates were 
prepared and subjected to MARCoNI analyses. The plots represent the mean signal intensity +/- the standard error of the mean (SEM) of 
3 biological replicates. Coregulators responding statistically significant to Dex treatment are displayed and were ranked according to Dex 
response. Statistical analysis was performed in R, using Welch t-tests corrected for multiple testing using the false discovery rate (FDR, 5%).
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Table 1: Significant coregulators upon Dex treatment 
per cell line. A Welch t-test was used to identify 
coregulators that significantly respond to Dex 
treatment per cell line. The p-values were corrected 
for multiple testing using FDR (5%).
MM1.S
coregulator p-value
NCOA2_733_755 0.00011
IKBB_277_299 0.00014
PRGC2_146_166 0.00014
NCOA3_725_747 0.00019
NRIP1_488_510 0.00019
PRGC2_338_358 0.00115
NR0B1_68_90_C69S 0.00115
MLL2_4175_4197 0.00115
PRGC1_130_155 0.00208
NCOA1_677_700 0.00226
NR0B1_136_159 0.00297
NRIP1_805_831 0.00297
MAPE_249_271 0.00297
NCOA1_1421_1441 0.00337
NRIP1_368_390 0.00447
NCOA3_609_631 0.00488
PELP1_56_78_C71S 0.00488
TIP60_476_498 0.00488
NRIP1_924_946 0.00527
TIF1A_747_769 0.00611
NRIP1_924_946_C945S 0.00619
NCOA2_628_651 0.00639
PRGC1_134_154 0.00738
NRIP1_253_275_C263S 0.00738
UBE3A_649_671 0.00738
NSD1_894_916 0.00738
NR0B2_9_31_C9S/C11S 0.00791
NR0B2_106_128 0.00889
ZNHI3_89_111 0.00965
BL1S1_1_11 0.01144
NRIP1_1055_1077 0.01188
JHD2C_2054_2076 0.01206
NCOA3_673_695 0.01206
(Continued )
MM1.S (Continued )
coregulator p-value
CHD9_855_877 0.01206
NCOA2_677_700 0.01349
TREF1_168_190 0.01439
NCOA3_609_631_C627S 0.01492
LCOR_40_62 0.01543
MED1_632_655 0.01576
WIPI1_119_141 0.01682
PR285_1105_1127 0.01683
CBP_57_80 0.01746
NRIP1_120_142 0.01771
NCOA1_737_759 0.01812
NRIP1_121_143_P124R 0.01984
NRIP1_701_723 0.02870
NCOR2_649_671_C649S 0.02870
MED1_591_614 0.03035
TRRAP_971_993 0.03035
MAPE_454_476_C472S 0.03533
PELP1_446_468 0.03977
CENPR_159_177 0.04460
PELP1_20_42 0.04577
NCOR1_2039_2061 0.04638
MTA1S_388_410_C393S/
C396S 0.04964
C7-14
coregulator p-value
NCOA3_725_747 0.00278
NR0B1_68_90_C69S 0.00467
NR0B1_136_159 0.00601
NRIP1_805_831 0.00698
NRIP1_924_946_C945S 0.00698
NRIP1_924_946 0.00698
NRIP1_368_390 0.01426
NCOA1_1421_1441 0.01496
PRGC1_134_154 0.01738
NCOA2_733_755 0.01738
UBE3A_649_671 0.01738
NCOA1_677_700 0.03047
(Continued )
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(NR0B2) and DAX-1 (NR0B1) as the coregulators 
with the highest signal intensities. However, for 3/55 
coregulators the signal intensity of the Dex response was 
significantly lower compared to solvent; these were the 
corepressors NCOR1, NCOR2 and PRAME (or MAPE) 
(Figure 1A). In C7-14 cells, the signal intensities were 
about two-fold higher than in the GC-resistant counterpart 
C1-15, with SRC-1 (NCOA1), PGC-1ɑ (PRGC1), SRC-
3 (NCOA3), RIP140 (NRIP1) and SRC-2 (NCOA2) 
displaying the highest signal intensities. Although the 
number of significant coregulator peptides in C7-14 (18) 
might seem larger than in C1-15 (11), these were mostly 
different peptides of the same coregulator (Figure 1C, 1D). 
Nevertheless, the strongest interacting coregulators in C1-
15 were SRC-3 (NCOA3), SRC-1 (NCOA1), RIP140 
(NRIP1), SRC-2 (NCOA2) and DAX-1 (NR0B1).
In summary, we extended the MARCoNI technology 
to the level of the endogenous GR in cell lysates and 
determined the coregulator profile of MM and ALL cell lines.
Comparison of the GR coregulator profiles of 
GC-sensitive MM and ALL cells
We used MARCoNI to further characterize the 
similarities and differences in the endogenous GR 
coregulator profile of GC-sensitive MM (MM1.S) and 
ALL (C7-14) cells, following 2h treatment with solvent 
(EtOH) or Dex. The Venn-diagram (Figure 2A) displays 
the number of significantly responding coregulator 
peptides upon Dex treatment when comparing MM1.S 
with C7-14 cells. We found 0 coregulator peptides in 
C7-14 alone (C7-14Dex), 37 in MM1.S alone (MM1.SDex) 
and 18 in both C7-14 and MM1.S (intersect) (Figure 
2A). We further subdivided the coregulator peptides of 
each segment of the diagram into 2 groups. One group 
(upper bar charts) contains the coregulator peptides 
for which the Dex response is not different between 
the cell lines of the comparison. The second group 
(lower bar charts) contains the coregulator peptides 
with a differential Dex response between the cell lines 
(Figure 2A).
Zooming in on the intersect, there was 1 coregulator 
peptide for which the Dex responses between MM1.S 
and C7-14 were not different and 17 coregulator peptides 
with differential Dex response between the cell lines 
(Figure 2A). Together, these 18 coregulator peptides were 
termed common between MM1.S and C7-14 and the 
corresponding signal intensities are depicted in Figure 2B. 
For instance, for PRGC1_134_154 the signal intensity in 
MM1.S was about four-fold higher than in C7-14 (Figure 
2B). Moreover, the coregulators with the highest signal 
intensities in MM1.S and C7-14 were PGC-1ɑ (PRGC1), 
SRC-1 (NCOA1), SRC-3 (NCOA3), DAX-1 (NR0B1) 
and RIP140 (NRIP1).
The MM1.SDex segment showed 15 coregulator 
peptides with a Dex response that was not different 
from the Dex response in C7-14, while there were 22 
coregulator peptides with a differential Dex response 
between the cell lines (Figure 2A). Therefore, only the 
latter 22 coregulator peptides could be termed unique 
for MM1.S when compared to C7-14 and their signal 
intensities are presented in Figure 2C. Moreover, the list 
of unique coregulator peptides of the first cell line of 
the comparison must always be verified with the list of 
significant coregulator peptides in the second cell line. If 
a coregulator peptide is present in both lists, or different 
coregulator peptides for the same coregulator are present 
in both lists, then the corresponding coregulator cannot 
be designated unique in one cell line. For instance, 
NR0B2_106_128 (Figure 2C) was listed as unique 
in MM1.S, but still showed a considerable, but not 
significant, Dex response in C7-14 (Figure 2C). In this 
case, the statistical procedure did not distinguish between 
no significant response upon treatment and no significant 
response due to large SEM. In addition, though 
NCOA2_628_651 was listed as a unique coregulator 
peptide in MM1.S, it is only one out of four coregulator 
peptides that represent SRC-2 (NCOA2) (Figure 
2C). Since another SRC-2 coregulator peptide, i.e. 
NCOA2_733_755, was present in the list of significant 
coregulators in C7-14 (Table 1), SRC-2 cannot be truly 
C7-14 (Continued )
coregulator p-value
TIF1A_747_769 0.03216
PRGC2_338_358 0.03589
PRGC1_130_155 0.04393
NRIP1_253_275_C263S 0.04668
PRGC2_146_166 0.04668
PELP1_446_468 0.04668
C1-15
coregulator p-value
NCOA3_725_747 0.00508
NRIP1_368_390 0.00508
NRIP1_924_946_C945S 0.00508
NCOA2_733_755 0.00848
PRGC2_146_166 0.01986
NR0B1_136_159 0.03062
NRIP1_805_831 0.04223
NR0B1_68_90_C69S 0.04223
NRIP1_924_946 0.04223
NCOA1_1421_1441 0.04452
UBE3A_649_671 0.04586
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considered as a unique coregulator in MM1.S. Therefore, 
the top five coregulators that are truly unique in MM1.S 
were TRIP3 (ZNHI3), PRAME (MAPE), NFKBIB 
(IKBB), JMJDAC (JHD2C) and LCOR (Figure 2C).
Comparison of the GR coregulator profiles of 
GC-sensitive and GC-resistant ALL cells
To identify common and unique coregulators of 
endogenous GR between GC-sensitive (C7-14) and GC-
resistant (C1-15) ALL cell lines, we treated these cells 
for 2h with solvent or Dex and applied the MARCoNI 
technology. The number of coregulator peptides that were 
significantly triggered upon Dex (Figure 3A) was: 0 in 
C1-15 alone (C1-15Dex), 7 in C7-14 alone (C7-14Dex) and 
11 in both C1-15 and C7-14 (intersect).
More in detail, in the intersect segment 10 
coregulator peptides did and 1 did not show a 
differential Dex response between the cell lines. 
Together these 11 coregulator peptides were considered 
as common between C7-14 and C1-15 and their signal 
intensities are displayed in Figure 3B. Interestingly, 
the signal intensities in the GC-sensitive C7-14 cells 
were consistently about two-fold higher than in the 
GC-resistant C1-15 cells. For these cell lines, the 
coregulators with the highest signal intensities were: 
SRC-1 (NCOA1), SRC-3 (NCOA3), RIP140 (NRIP1), 
SRC-2 (NCOA2) and DAX-1 (NR0B1).
Remarkably, we did not identify coregulators that 
were unique for either C1-15 or C7-14. For C7-14 we did 
find 7 coregulator peptides that respond significantly to 
Dex treatment, but the Dex response in C7-14 was not 
Figure 2: Comparing GR coregulator profiles of GC-sensitive ALL and MM cells. C7-14 (ALL) and MM1.S (MM) cells were 
treated for 2h with solvent or Dex (1μM). Protein lysates were prepared and subjected to MARCoNI analyses. (A) The Venn-diagram shows 
the number of coregulators that respond significantly to Dex treatment in C7-14, MM1.S, or in both. For each segment of the Venn-diagram, 
coregulator peptides are further subdivided into 2 groups depending on whether the Dex responses were different (lower bar charts) or not 
(upper bar charts) between the cell lines; accompanied by the actual number of coregulators that display such a response. Coregulators 
defined as common or unique between C7-14 and MM1.S are indicated. (B) Common coregulators between C7-14 and MM1.S, (C) unique 
coregulators for MM1.S compared to C7-14. The plots represent the mean signal intensity +/- SEM of 3 biological replicates. Coregulators 
responding statistically significant to Dex treatment are displayed and were ranked according to Dex response in MM1.S. Statistical 
analysis was performed in R, using Welch t-tests corrected for multiple testing using FDR (5%).
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different from the Dex response in C1-15 and thus these 
coregulator peptides cannot be defined as truly unique for 
C7-14.
Comparison of the GR coregulator profiles of 
MM and lung carcinoma cells
We also compared the endogenous GR 
coregulator profile of a lymphoid malignancy (MM, 
e.g. MM1.S) with a solid cancer (lung carcinoma, e.g. 
A549), following 2h stimulation with solvent or Dex. 
Supplementary Figure 2 shows the coregulator peptides 
that are significantly different upon Dex treatment in 
A549 cells, together with their corresponding p-values 
(Supplementary Table 1). In A549 cells, RIP140 
(NRIP1), SRC-1 (NCOA1), PGC-1ɑ (PRGC1), TRIP-
3, (ZNHI3) and SRC-3 (NCOA3) were the coregulators 
with the highest signal intensity. Remarkably, 8 
coregulator peptides, for instance NCOR1_2039_2061, 
showed a significant drop in signal intensity upon Dex 
treatment.
Figure 4A displays the number of coregulator 
peptides that significantly responded to Dex treatment: 8 in 
A549 alone (A549Dex), 20 in MM1.S alone (MM1.SDex) and 
35 in both A549 and MM1.S (intersect). In the intersect, 
11 coregulator peptides did not and 24 did display a 
differential Dex response between the cell lines. In total, 
these 35 coregulators peptides were in common between 
A549 and MM1.S cells and their corresponding signal 
intensities are shown in Figure 4B. Overall, the signal 
intensities in the MM1.S cells were up to three-fold higher 
than in A549 cells. The top five common coregulators 
between these cell lines are PGC-1ɑ (PRGC1), SRC-
1 (NCOA1), SRC-3 (NCOA3), SHP (NR0B2), DAX-1 
(NR0B1).
No unique coregulators could be identified in 
A549 cells compared to MM1.S cells. Yet, 8 coregulator 
peptides were differentially regulated upon Dex 
treatment in A549 cells and not in MM1.S cells, but 
their corresponding Dex responses did not differ and 
thus these could not be defined as unique. In MM1.S 
cells, 4 unique coregulator peptides were found and 
their signal intensities are shown in Figure 4C. However, 
these 4 coregulator peptides still show a considerable 
Dex response in A549 cells (Figure 4C). In this case, the 
statistical procedure could not differentiate between no 
significant response upon treatment and no significant 
response due to large SEM.
Figure 3: Comparing GR coregulator profiles of GC-sensitive and -resistant ALL cells. C1-15 (GC-resistant) and C7-14 
(GC-sensitive) cells were treated for 2h with solvent or Dex (1μM). Protein lysates were prepared and subjected to MARCoNI analyses. 
(A) The Venn-diagram shows the number of coregulators that respond significantly to Dex treatment in C1-15, C7-14, or in both. For each 
segment of the Venn-diagram, coregulator peptides are further subdivided into 2 groups depending on whether the Dex responses were 
different (lower bar charts) or not (upper bar charts) between the cell lines; accompanied by the actual number of coregulators that display 
such a response. Coregulators defined as common between C1-15 and C7-14 are indicated. (B) Common coregulators between C1-15 and 
C7-14. The plot represents the mean signal intensity +/- SEM of 3 biological replicates. Coregulators responding statistically significant 
to Dex treatment are displayed and were ranked according to Dex response in C7-14. Statistical analysis was performed in R, using Welch 
t-tests corrected for multiple testing using FDR (5%).
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Validation of endogenous GR-SRC-1 interaction 
and correlation with GR protein levels
To validate the MARCoNI results, we determined 
whether GR interacts with SRC-1 at the endogenous level 
in MM1.S, C7-14 and C1-15 cells, as SRC-1 appeared 
as one of the strongest interacting coregulators of GR in 
all cell line comparisons. To this end, we treated MM1.S, 
C7-14 and C1-15 cells for 2h with solvent or Dex, 
immunoprecipitated GR and assayed its interaction with 
SRC-1 via Western blot (WB) analysis. Figure 5A-5C 
shows that immunoprecipitation of GR was successful 
in all cell lines, as evidenced by the presence of a GR 
band in the IP fraction (lanes 5 and 6), and its absence 
in lane 4 (aspecific antibody control). Supplementary 
Figure 3A-3C includes the HEK293T positive control 
for the SRC-1 antibody, which confirmed its specificity 
and indicated that the SRC-1 band is located at 180kDa. 
Moreover, SRC-1 was present in the immunoprecipitation 
(IP) fraction of all cell lines, confirming the interaction 
between SRC-1 and GR (Figure 5A-5C, lanes 5 and 6). 
In MM1.S and C1-15 cells, Dex treatment did not alter 
the SRC-1 levels in the IP fraction, while in C7-14 cells 
the levels of SRC-1 were slightly increased upon Dex 
treatment (Figure 5A-C).
We also wondered whether GR protein levels in 
MM1.S, C7-14 and C1-15 corresponded to the observed 
signal intensities in the MARCoNI assay. Therefore, we 
determined GR protein levels in these cell lines after 
2h treatment with solvent or Dex and quantified these 
by densitometric analysis (Supplementary Figure 4A). 
In the absence of ligand, GR protein levels were the 
highest in C7-14, then in MM1.S and the lowest in C1-15 
(Figure 5D). Upon Dex stimulation, GR levels underwent 
homologous downregulation, albeit to a varying degree 
that depended on the cell line. MM1.S displayed the 
lowest GR levels upon Dex treatment, although these 
cells showed the highest MARCoNI signal intensity. 
GC-sensitive C7-14 cells did not only exhibit higher GR 
protein levels than GC-resistant C1-15 cells in response 
to Dex, but also displayed the strongest signal for an 
additional GR isoform around 80kDa.
Figure 4: Comparing GR coregulator profiles of lung carcinoma and MM cells. A549 (lung carcinoma) and MM1.S (MM) 
cells were treated for 2h with solvent or Dex (1μM). Protein lysates were prepared and subjected to MARCoNI analyses. (A) The Venn-
diagram shows the number of coregulators that respond significantly to Dex treatment in A549, MM1.S, or in both. For each segment of 
the Venn-diagram, coregulator peptides are further subdivided into 2 groups depending on whether the Dex responses were different (lower 
bar charts) or not (upper bar charts) between the cell lines; accompanied by the actual number of coregulators that display such a response. 
Coregulators defined as common or unique between A549 and MM1.S are indicated. (B) Common coregulators between A549 and MM1.S, 
(C) unique coregulators for MM1.S compared to A549. The plot represents the mean signal intensity +/- SEM of 3 biological replicates. 
Coregulators responding statistically significant to Dex treatment are displayed and were ranked according to Dex response in MM1.S. 
Statistical analysis was performed in R, using Welch t-tests corrected for multiple testing using FDR (5%).
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Summarized, our results confirmed the interaction 
between endogenous GR and SRC-1 in MM1.S, C7-14 
and C1-15 cells and suggested that GR protein levels do 
not correlate with the signal intensity of the MARCoNI 
assay.
Endogenous GR levels and coregulator profile of 
PBMCs
As a step towards patient samples, we isolated 
PBMCs from healthy volunteers, assayed GR protein 
levels, quantified these by densitometric analysis 
(Supplementary Figure 4B) and determined the 
corresponding coregulator profile after 2h stimulation with 
solvent or Dex. Figure 6A shows that upon Dex treatment, 
GR protein levels were either downregulated, unaltered, 
or even increased, indicating that GR protein levels in 
PBMCs are quite variable. Figure 6B demonstrates that 
Dex treatment did not differentially affect the signal 
intensity of the coregulator peptides compared to solvent. 
This is conceivable since endogenous cortisol that is 
present in blood can influence the signal intensity. In this 
case, the solvent control cannot be considered as a true 
negative control due to the endogenous cortisol levels. 
Nevertheless, coregulator peptides with signal intensities 
above 50 could still be considered as interactors of 
endogenous GR. The top five coregulators in PBMCs are 
therefore: SRC-1 (NCOA1), H3-K36-HMT (NSD1), SRC-
3 (NCOA3), RIP140 (NRIP1) and PNRC2.
DISCUSSION
In this report, we determined the coregulator profile 
of endogenous GR in cell lysates of MM, ALL, lung 
carcinoma cell line models and PBMCs. The interaction 
profile of coregulators with NRs is defined by different 
factors. The origin of both the ligand, i.e. synthetic or 
endogenous, and the NR, i.e. endogenous, overexpressed 
or recombinant, affects the NR conformation, PTM-status 
and ultimately the recruitment of certain coregulators [26, 
30]. Desmet et al. recently showed that the combination 
of Dex with the selective GR modulator compound A 
(CpdA) gave rise to altered GR coregulator recruitment. 
NR0B2 (SHP) interacted more strongly with GR upon 
Dex/CpdA combination compared to Dex alone [31]. Vice 
versa, the recruited coregulators that interact with the NR 
can influence the NR conformation and PTM-status and 
undergo PTMs themselves. For instance, SMRT (NCOR2) 
phosphorylation by ERK2 was shown to disrupt the 
SMRT-corepressor complex and inhibited transcriptional 
repression [32]. Also, the cell type specific expression 
and competition between coregulators co-determines 
the NR-coregulator interaction profile. Altogether, these 
factors substantiate the reason why so far more than 400 
coregulators have been identified [5, 26].
We extended the MARCoNI technology to 
monitor coregulator associations with endogenous GR 
in cell lysates [26]. So far, coregulator profiling from 
cell and tumor lysates was only reported for ERɑ [27]. 
The major advantage of this technology is that it allows 
the simultaneous detection of up to 67 coregulator-NR 
Figure 5: Endogenous GR levels and interaction with SRC-1 in MM and ALL cells. (A) MM1.S, (B) C7-14, (C) C1-15 cells 
or (D) MM1.S, C7-14 and C1-15 cells were treated for 2h with solvent or Dex (1μM). Protein lysates, (A-C) NP-40-based or (D) M-PER-
based, were prepared and endogenous GR co-immunoprecipitation (A-C) was performed, followed by WB analysis to detect the protein 
levels of GR (90-95kDa) or SRC-1 (180kDa), with GAPDH (37kDa) serving as loading control. As a negative control for IP, a non-specific 
antibody was used (lane 4). WB results are representative for 2 (A-C) or 3 (D) independent experiments.
Oncotarget109684www.impactjournals.com/oncotarget
interactions, yet, there are also limitations. For instance, 
there can be competition between the coregulator peptides 
and endogenous coregulators present in the cell lysate 
for binding the NR, which can mask interactions on the 
PamChip [26]. Given that coregulators are expressed in 
a cell-type specific manner, certain interactions between 
a coregulator peptide and the NR could also be artificial 
if the coregulator is not endogenously present in the 
cell lysate. Moreover, neither coregulator PTMs nor 
the promoter context that influences NR conformation 
and coregulator recruitment [3], nor other TFs that bind 
to target gene promoters and their affiliate coregulators 
are considered by this technology. Nevertheless, the 
MARCoNI technology has proven to be one of the only 
tools that permits simultaneous screening of a vast number 
of coregulator-NR interactions [31, 33, 34]. Moreover, 
MARCoNI may prove useful to dissect coregulator profile 
changes in a pathological setting, given that coregulators 
are master regulators of diseases [2].
Using MARCoNI, we identified SRC-1/2/3, PGC-
1ɑ, RIP140 and DAX-1 as the strongest interacting 
coregulators of MM and ALL cells. The highest 
MARCoNI signal intensities were found in MM1.S cells 
compared to C7-14 and C1-15 cells. It is conceivable 
that the number of GR units (not total GR content) that 
interacts with a certain coregulator peptide to produce a 
signal is different between cell lines, resulting in different 
signal intensities between cell lines. We speculate that 
the affinity of endogenous GR for coregulators may be 
higher in MM1.S cells, compared to the other cell lines, 
indicating that the affinity of NRs for coregulators may 
well be cell-type specific. In addition, the PTM-status 
of the NR can influence the obtained MARCoNI signal 
intensity. Indeed, for ERɑ it was shown that increased ERɑ 
Ser305 phosphorylation induced increased coregulator 
binding [27]. Moreover, GR Ser211 phosphorylation was 
shown to increase transcriptional activity by promoting a 
conformation change that facilitates coregulator binding 
[35]. In this context, Lynch and co-workers compared GR 
Ser211 and Ser226 phosphorylation in C7-14 and C1-
15 cells and found that GR Ser211 phosphorylation was 
predominant in C7-14 cells, while for C1-15 cells this was 
Figure 6: Endogenous GR levels and coregulator profile of PBMCs. PBMCs were isolated and treated for 2h with solvent or 
Dex (1μM). Protein lysates were prepared and subjected to (A) WB or (B) MARCoNI analyses. (A) WB analysis was performed to detect 
the protein levels of GR (90-95kDa), GAPDH (37kDa) served as loading control. WB results represent two independent PBMC isolations 
of each time 3 biological replicates. (B) The coregulator plot represents the mean signal intensity +/- SEM of 3 biological replicates. Data 
analysis was performed in R.
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GR Ser226 phosphorylation [36]. This difference might 
serve to explain the higher MARCoNI signal intensities in 
C7-14 cells versus C1-15 cells.
Moreover, most coregulators that responded 
significantly to Dex treatment in MM1.S, C7-14 or C1-
15 cells displayed increased signal intensity, which means 
that an interaction between GR and a certain coregulator 
takes place upon ligand induction. However, in a few 
cases the signal intensity dropped upon Dex stimulation. 
It is conceivable that in the absence of ligand a proportion 
of coregulators are constitutively bound to the NR. Upon 
NR stimulation, these interactions are lost and would 
result in decreased signal intensity in the MARCoNI 
assay. For instance, we observed this response for the 
corepressors NCOR1 and NCOR2 in MM1.S and A549 
cells, but also for e.g. the coactivator CBP in A549 cells. 
The latter exemplifies the concept that coactivators can 
act as corepressors and vice versa [3]. In this context, the 
group of Rogatsky showed that the coactivator GRIP1 
(SRC-2) facilitated GC-induced anti-inflammatory actions 
in vivo by acting as a corepressor [5]. Also MTA1, a 
known corepressor for ERɑ, was shown to function as a 
coactivator for the gene BCAS3 that was described to be 
overexpressed and amplified in breast cancer [37].
We showed that GC-sensitive MM1.S compared to 
C7-14 cells display a more dynamic coregulator profile. 
We propose that this arises from a more GC-responsive 
GR in MM1.S cells compared to C7-14 cells, which would 
be also conformationally more flexible to interact more 
strongly and with a wider range of coregulators. The 
group of Yamamoto recently showed that GR plasticity 
is an important factor in the regulation of transcription 
[30], supporting our hypothesis. This is in line with 
why unique coregulators could only be identified in 
MM1.S. Yet, in MM1.S we also identified 15 coregulator 
peptides that responded to Dex treatment, but for which 
the Dex response was not different from the one in C7-
14. We suggest that these coregulator peptides represent 
coregulators that are constitutively bound to GR.
Moreover, we found that PGC-1ɑ, SRC-1/3, DAX-1 
and RIP140 were the coregulators with the highest signal 
intensities between MM and ALL cell lines. Up to now, the 
role of coregulators in hematological malignancies is not 
well characterized. In MM, STAT3 was shown to recruit 
CBP/p300 coactivators for the transactivation of its target 
genes, a process in which SRC-1 is generally not required, 
and thereby promotes growth and inhibits apoptosis of 
MM cells [38, 39]. Negative modulation of STAT3 by 
peroxisome proliferator activated receptor γ (PPARγ) 
and ER was shown in MM via a direct mechanism or by 
recruitment of the coregulators NCOR2 or PIAS [38]. 
Moreover, in acute myeloid leukemia (AML) the HAT 
monocytic leukemia zinc finger protein (MOZ) was shown 
to generate fusion proteins with the coactivators p300, CBP 
and SRC-2 via chromosomal translocations [40]. These 
MOZ fusion genes deregulate MOZ-controlled target gene 
transcription and thereby repress differentiation, induce 
hyperproliferation and disturb normal hematopoiesis [40]. 
Also, in chronic lymphoid leukemia (CLL), transcriptional 
profiling of chromosome 2p gain CLL cells identified, 
amongst others, SRC-1 to be significantly upregulated 
in these cells [41]. In contrast, in B-cell lymphoma the 
presence of SRC-3 was shown to have anti-proliferative 
effects [42]. This suggests that the SRC coregulator family 
may have opposing effects in lymphoid malignancies, i.e. 
pro-proliferative versus anti-proliferative, depending on 
the cell type. In addition, Millard et al. suggest that the 
SMRT/NCOR complex, containing HDAC3, might be 
a key target in diseases for which pan-HDAC inhibitors 
have proven their use [43]. MM serves as an example, as 
the pan-HDAC inhibitor panobinostat has been approved 
for the treatment of relapsed/refractory MM patients who 
had two prior lines of treatment [44] and since HDAC3 
was recently identified as a novel therapeutic target in MM 
as HDAC3 inhibitors were shown to induce MM cell death 
[45].
We identified SRC-1 (NCOA1), SRC-3 (NCOA3), 
RIP140 (NRIP1), SRC-2 (NCOA2) and DAX-1 (NR0B1) 
as the strongest interacting coregulators of endogenous GR 
in GC-sensitive C7-14 and GC-resistant C1-15 cells. The 
MARCoNI signal intensities in the C7-14 cells were vastly 
higher than in C1-15 cells, suggesting that the affinity of 
GR for coregulators may be higher in C7-14 than in C1-
15 cells. Moreover, since GR is more GC-responsive in 
C7-14 cells compared C1-15 cells, it also explains why 7 
coregulator peptides respond to Dex exclusively in C7-14 
cells compared to 0 in C1-15 cells. We propose that GR 
is more flexible in C7-14 cells to interact more strongly 
and with more coregulators, while GR seems more rigid 
to do so in C1-15 cells. However, we did not find unique 
coregulators for either cell line, indicating that GC 
resistance in C1-15 cells cannot be explained by qualitative 
but more likely (partly) by quantitative differences in the 
coregulator profile, possibly also arising from a more rigid 
GR in C1-15 cells. Coregulators have been implicated 
in GC and therapy resistance before. GC-induced GR 
gene repression was shown to be conveyed by blocking 
transcription initiation via the formation of a long-range 
interaction between an NCOR1-containing complex at 
the transcription start site and an intragenic negative GC 
response element (nGRE). In this sense, long-term GC 
treatments could lead to constitutive GR gene repression 
and by extension GC resistance [25]. In breast cancer, SRC-
3 overexpression has been linked to resistance to therapy 
[46–48]. Moreover, patients with high SRC-3 and HER-2 
expression levels showed worse outcomes with antiestrogen 
therapy compared to all other breast cancer patients together 
[46]. In addition, a mutation in ERɑ was shown to cause 
constitutively activation of ERɑ by recruiting coactivators in 
the absence of ligand and caused resistance to antiestrogen 
therapy by altering conformational changes in the ERɑ 
ligand binding domain [48].
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We found PGC-1ɑ, SRC-1, SRC-3, SHP and DAX-
1 as the top five common coregulators upon comparison 
of MM (MM1.S) cells with lung carcinoma (A549) 
cells. Although we found unique coregulator peptides 
for MM1.S cells, these coregulators still displayed a 
considerable Dex response, and were considered as false 
positives. In lung carcinoma cells, we did not identify 
coregulators that are uniquely expressed in these cells. Cai 
et al. showed that SRC-3 was found to be overexpressed in 
27% of non-small cell lung carcinomas and was associated 
with rapid progression of the disease [2, 6, 49]. Besides in 
lung and breast cancer, coregulators have been implicated 
in other solid malignancies, such as prostate, endometrial 
and ovarian cancer, and in melanoma [2, 50]. For instance, 
in prostate cancer miR137 was show to suppress androgen 
signaling by modulating the expression of a range of 
coregulators including SRC-2 [51]. Moreover, Dasgupta 
and colleagues found that SRC-2 inhibition in mice 
strongly attenuates prostate cancer cell growth, survival 
and metastasis [52].
We confirmed the interaction of GR with SRC-1 
by endogenous co-immunoprecipitation, albeit a ligand-
dependent effect was largely lacking. An increase in 
SRC-1 protein levels upon Dex treatment was only 
observed in C7-14 cells. This may reflect differences in 
how interactions are probed by IP/WB (static) compared 
to MARCoNI (dynamic, real-time). Nevertheless, this 
suggests that co-immunoprecipitation is a suitable 
strategy to qualitatively rather than quantitatively validate 
coregulator-NR interactions. In addition, we found that 
GR protein levels do not seem to correlate with the 
MARCoNI signal intensity. Indeed, MM1.S cells showed 
the highest signal intensities compared to C7-14 and C1-
15 cells, but showed the lowest GR protein levels upon 
Dex treatment. This confirms that not GR protein levels, 
but the affinity of GR for the coregulators determines 
the MARCoNI signal intensity and thus their interaction 
strength. Moreover, we realize that GR levels responded 
differently to Dex treatment in Figure 5A-5C compared 
to Figure 5D, although the same induction time was used. 
These differences seem to arise from the use of different 
lysis buffers, since this was the major difference between 
these experiments.
We found that GR protein levels varied in PBMCs 
depending on the healthy volunteer from which the 
PBMCs were derived. In addition, we found that 
GC stimulation of PBMCs (mostly) did not alter the 
coregulator signal intensities compared to solvent. It is 
conceivable that some individuals may have had higher 
endogenous cortisol levels in their blood at the time 
of blood sampling, which is a stressful event. A rise in 
cortisol levels could further influence both GR protein 
levels and limit the response to synthetic GCs, as GR was 
probably saturated with endogenous cortisol. Obtaining 
a proper negative control in this context is technically 
challenging due to circadian and ultradian GC secretion 
with even inter-person variability [53]. Nevertheless, 
coregulator peptides with signal intensities above 50 
were considered as interaction partners of GR, as the 
signal intensities of the cell line solvent conditions were 
never higher than 50. Therefore, SRC-1 (NCOA1), H3-
K36-HMT (NSD1), SRC-3 (NCOA3), RIP140 (NRIP1) 
and PNRC2 were identified as the strongest interacting 
coregulators of endogenous GR in PBMCs as they 
displayed the highest signal intensities. Although, we 
do have to remark that the coregulator peptides that 
respond to Dex treatment in case of SRC-3 and RIP140 
are different in PBMCs compared to those in MM/ALL 
cells. This might be explained by different conformational 
changes in GR, that depend on the ligand, i.e. Dex in MM/
ALL and cortisol in PBMCs. Since we have shown that 
coregulator profiling of PBMCs is technically possible, 
it can be considered that coregulator profiling of MM/
ALL cells from patient samples is also a feasible goal. It 
would also be interesting in the future to even compare 
PBMCs of actual patients with MM/ALL to learn whether 
they would respond different from what is now observed 
in healthy volunteers. In extension, coregulator profiling 
could be even used for monitoring response to therapy in 
patients over time.
SRCs have been implicated in proliferation, survival 
and metastasis of cancer cells and in therapy resistance, 
and thus represent key targets for the development of 
novel anti-cancer drugs [50]. In contrast to targeted 
chemotherapeutics, which block one signaling pathway, 
SRC-directed drugs would simultaneously target multiple 
pathways and could overcome aspects of acquired 
resistance mechanisms [54]. However, their development 
is hampered by the fact that SRCs lack a high affinity 
ligand binding domain as well as a defined enzymatic 
activation surface [7]. Nevertheless, the high-throughput 
screening of a chemical library identified the structurally 
unrelated bufalin and verrucarin A as SMI inhibiting the 
transcriptional activity of SRCs [7]. Although bufalin 
directly binds and degrades SRC-3 and SRC-1 via the 
proteasome and blocks cancer cell growth in vitro and 
in vivo, verrucarin selectively degrades SRC-3 without 
physically interacting with it and blocks cancer cell 
proliferation and migration [7, 55, 56]. Recently, also 
SI-2 was identified as a highly promising SMI of SRC-
3 that selectively reduces both its transcriptional activity 
and concentration and potently reduces BC cell viability 
[57]. In contrast to SMIs, also small molecule stimulators 
(SMSs), such as MCB-613, have been developed. MCB-
613 hyperstimulates the transcriptional activity of SRCs, 
thereby overloading the stress response of the cancer cells 
which ultimately kills them [58]. Since the SRC’s are also 
prominently activated by GCs in MM and ALL cells, we 
suggest therapeutic exploration of SRC SMIs and SMSs in 
hematological malignancies.
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MATERIALS AND METHODS
Cell lines and reagents
Human multiple myeloma cells (MM1.S) and 
acute lymphoblastic leukemia cells (CEM-C7-14 and 
CEM-C1-15) were cultured in RPMI1640 glutamax 
(Gibco, life technologies) supplemented with 10% fetal 
calf serum (Greiner bio-one), 100U/mL penicillin and 
0.1mg/mL streptomycin (Gibco, life technologies), and 
were grown in a 5% CO2 incubator at 37°C. MM1.S 
cells were purchased from ATCC, CEM-C7-14 and 
CEM-C1-15 cells were kind gifts from Prof. Brad E. 
Thompson (University of Texas Medical Branch). Human 
embryonic kidney cells (HEK293T) and human lung 
carcinoma cells (A549) were cultured in DMEM (Gibco, 
life technologies) supplemented with 10% fetal calf serum 
(Greiner bio-one), 100U/mL penicillin and 0.1mg/mL 
streptomycin (Gibco, life technologies), and were grown 
in a 5% CO2 incubator at 37°C. HEK293T and A549 cells 
were obtained from the nuclear receptor lab (NRL) (VIB-
UGent). All experiments were performed using charcoal-
stripped serum (Gibco, life technologies) to eliminate the 
influence of endogenous hormones present in fetal calf 
serum. All cell lines were regularly tested for mycoplasma 
contamination and were negative.
The glucocorticoid dexamethasone (Dex) was 
purchased from Sigma Aldrich and dissolved in EtOH. In 
all experiments the total solvent concentration was kept 
equal in each condition.
Protein lysates and Western blotting (WB)
Cells were induced as indicated in the figure 
legends. Protein lysates were prepared by: 1) Totex 
lysis buffer (Hepes/KOH pH=7.9 20mM, NaCl 350mM, 
glycerol 20%, NP-40 1%, MgCl2 1mM, EDTA 0.5mM, 
EGTA 0.1mM) for PBMC samples or 2) M-PER 
(Mammalian Protein Extraction Reagent) lysis buffer 
(ThermoFisher Scientific) for MM1.S, C7-14 and C1-15 
cells, or 3) NP-40 lysis buffer (1% NP-40, 50mM Tris-
HCl pH 8.0, 150mM NaCl) for co-immunoprecipitation. 
All lysis buffers were freshly supplemented with Halt 
protease and phosphatase inhibitor cocktail, EDTA-free 
(ThermoFisher scientific). Next, the protein concentration 
of the samples was measured via the Lowry method 
using the DC protein assay (Bio-Rad). 25μg (or less) of 
total protein was denatured, loaded on a SDS-PAGE gel, 
blotted on a nitrocellulose membrane (Bio-Rad), followed 
by standard antibody probing procedures (Santa Cruz 
Biotechnology).
As primary antibodies, we used: anti-GR (H300) 
(cat nr: sc-8992, Santa Cruz Biotechnology), anti-NCOA1 
(SRC-1) (cat nr: 128E7, Cell Signaling). As loading 
control, we used the following primary antibodies: anti-
GAPDH (cat nr: ab9485, Abcam), anti-GAPDH (cat nr: 
G8795, Sigma). As secondary antibodies, we used species-
specific HRP-conjugated antibodies (cat nr: NA931, 
NA934, GE-Healthcare). To visualize results, we used 
Pierce ECL (Thermo Fisher Scientific), Westernbright 
Quantum or Sirus (Isogen) as chemiluminescent substrates 
and developed using X-Ray films (GE healthcare) or 
imaged on a ProXima 2850 imaging system (Isogen). WB 
results were quantified via band densitometric analyses 
using ImageJ. Relative protein levels were obtained by 
dividing the area under the curve (AUC) of the protein of 
interest by the AUC of the loading control.
Peripheral blood mononuclear cell (PBMC) 
isolation
PBMCs were isolated from heparinized blood 
samples of healthy volunteers. Whole blood (20mL) was 
diluted with DPBS (ThermoFisher Scientific) in 1:1 ratio. 
As density centrifugation medium, Ficoll-Paque PLUS 
(GE healthcare) was used and 15mL was added to the 
SepMate tube (cat nr: 15460, 50mL format, StemCell 
Technologies) through the central hole of the SepMate 
insert. The diluted blood was added by pipetting it down 
the SepMate tube wall, followed by centrifuging the 
SepMate tube for 15’ at 1200g, room temperature (RT) 
with the brake on. The top layer containing the PBMCs 
and plasma is poured off in a fresh 50mL tube and is 
centrifuged for 8min at 300g, RT with the brake on. The 
supernatant is removed and the pellet is washed twice 
with RPMI1640 glutamax (Gibco, life technologies) 
supplemented with 2% fetal calf serum (Greiner bio-
one), 100U/mL penicillin and 0.1mg/mL streptomycin 
(Gibco, life technologies) and centrifuged for 8min at 
300g, RT with the brake on. Next, the cells were counted, 
transferred to a 6-well plate and induced for 2h with EtOH 
or Dex (1μM). Protein lysates were prepared using Totex 
lysis buffer.
Microarray assay for real-time coregulator 
nuclear receptor interactions (MARCoNI)
MM1.S, C7-14, C1-15, A549 cells and PBMCs were 
induced for 2h with EtOH or Dex (1μM) and collected 
by washing twice with ice-cold phosphate buffered saline 
(PBS). Protein lysates were prepared by addition of 
M-PER lysis buffer (or Totex lysis buffer for PBMCs), 
and were placed in a thermomixer (Eppendorf) for 5’ at 
1000rpm, RT. Next, the lysates were centrifuged together 
with the primary anti-GR (cat nr: sc-8992, Santa Cruz 
Biotechnology) and secondary anti-Alexa 488 antibody 
(cat nr: A-11070, ThermoFisher Scientific) for 1h at 
20000g, 4°C. Next, 25μL of assay mix is prepared per 
sample and contains 10μL of lysate, 1μL DTT (0.05mM), 
12.5μL 2x NR-buffer, 0.94μL anti-GR antibody (50nM 
for cell lines, 100nM for PBMCs) and was filled up to 
25μL with Milli-Q water. The PamChip arrays (Pamgene) 
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were placed in the Pamstation (Pamgene), operated by 
Evolve software, and blocked with 25μL StartingBlock 
buffer (ThermoFisher Scientific) per array. Then, 25μL 
assay mix/array is loaded, followed by washing steps, 
the addition of 25uL of anti-Alexa 488 (40nM for cell 
lines, 80nM for PBMCs) antibody, and final washing 
steps after which images of the arrays are taken at defined 
exposure times. The analysis of these images was done 
using BioNavigator software, which does automated spot-
finding, quantifies the spots and determines the signal-
over-background ratio. The resulting data was exported 
and further analyzed in R (see Statistical Analyses).
Co-immunoprecipitation (co-IP)
Cells were induced as specified in the figure legends 
and lysed in NP-40 lysis buffer. Immobilized (using 2mg/
mL BSA) Dynabeads (50μL bead slurry, cat nr: 11204D, 
ThermoFisher Scientific) were added to the lysate and 
rotated for 1h at 4°C. Using the Dyna-Mag 2 magnet 
(ThermoFisher Scientific) the supernatant (precleared 
lysate) was separated from the beads and the protein 
concentration was measured via the Lowry method (see 
above). Then, 150μg precleared lysate was combined 
with 5μL anti-GR antibody (cat nr: sc-8992, Santa Cruz 
Biotechnology) and rotated for 1h at 4°C. Immobilized 
Dynabeads (50μL bead slurry) were added to the mixture 
and rotated for another 2h at 4°C. The bead-mixtures 
were washed three times with NP-40 lysis buffer and 
were denatured for 5’ at 95°C using a thermomixer 
(Eppendorf). The samples were subjected to WB analysis 
and anti-NCOA1 (SRC-1) antibody (cat nr: 128E7, Cell 
Signaling) was used to assay the interaction between 
immunoprecipitated GR and NCOA1.
Transfection
HEK293T were transfected with pSRC1a using 
jetPRIME (Polyplus), following the manufacturer’s 
instructions. Cells were collected 24h post-transfection, 
after which protein lysates (Totex) were prepared and WB 
was performed.
Statistical analyses
Data analysis of the MARCoNI results was 
performed in R. The cutoff of the signal intensity was set 
at 10, and thus coregulators with a mean signal intensity 
lower than 10 were removed. Normalization of the data 
was performed using a local regression fit (loess), which 
subtracts a fitted value for each point from the observed 
value [59]. To this end, each technical replicate is 
normalized to a virtual reference (geometric mean of all 
replicates) and the degree of smoothing is controlled by 
a span parameter that is optimized to minimize the sum 
of deviations from the geometric mean. For the statistical 
analysis, an independent filtering procedure was applied 
to maximize hypothesis rejections and thus significant 
results [60]. It consisted of computing the variance for 
each coregulator across compared conditions, ranking the 
coregulators on variance from low to high and selecting 
the variance cutoff. In the next step, a Welch t-test, that 
does not assume equal variances, is used to compare the 
mean of two conditions. To correct for multiple testing, 
the false discovery rate (FDR) was used. Results were 
designated significant when the p-value (p) < 0.05.
Results are presented as scatter plots, in which the 
mean +/- standard error of the mean (SEM) are depicted. 
No statistical test was used to predetermine sample size, 
but we performed 3 (or more) biological replicates per 
MARCoNI experiment.
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PNRC2: proline-rich nuclear receptor coregulatory protein 
2, PPAR: peroxisome proliferator activated receptor, 
PRAME: preferentially expressed antigen in melanoma, 
PTM: post-translational modification, NR: nuclear 
receptor, RIP140: receptor-interacting protein 140, SHP: 
small heterodimer protein, SMI: small molecule inhibitor, 
SMS: small molecule stimulator, SRC: steroid receptor 
coactivator, TF: transcription factor, TRIP3: thyroid 
receptor interacting protein 3.
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